Progression-free survival not linked with quality of life

Few drug trials report on QoL, researcher says

 Cancer drugs that improve progression-free survival may not improve health-related quality of life, a study suggests.

"In countries where patients need to pay co-pays, they can use up all their savings in order to get access to those expensive new drugs and in the end, they may not extend their lives or improve their quality of life," Dr Feng Xie (PhD), a professor of health economics at McMaster University, said.

These days, cancer researchers and drug companies often use progression-free survival as a